Literature DB >> 16715674

Comparative study of vascular enhancement on post-contrast CT using three dosages of iodinated contrast media for the aim of detecting brain metastasis in patients with lung cancer.

Katsumi Hayakawa1, Toshiki Shiozaki, Akira Yamamoto, Soichi Kubo, Tsutomu Osako.   

Abstract

OBJECTIVE: A prospective double-blind randomized study was performed to compare the contrast of vascular enhancement using three dosages of iodinated contrast media for a possible metastatic lesion in the brain.
MATERIALS AND METHODS: Sixty-six patients with lung cancer received brain computed tomography (CT) with intravenous administration of iodinated contrast medium (CM). The patients were randomly assigned to receive one of the three types of CM: 30 g iodine, 24 g iodine, and 15 g iodine. Three radiologists judged the degree of vascular contrast enhancement and diagnosed the presence of brain metastasis. The CT numbers in major arteries were also measured.
RESULTS: The subjective average scores with standard deviation were 2.06+/-0.48, 1.97+/-048, and 1.44+/-0.43, and the measured average CT numbers with standard deviation (SD) were 168.5+/-39.6, 166.1+/-28.6, and 146.1+/-27.0 HU with 30 g, 24 g, and 15 g iodine, respectively. The scores and the CT numbers in 15 g iodine were less than those with 30 g and 24 g iodine. Brain metastasis was detected in one patient each in groups A and C, and one false-positive case was found in group B.
CONCLUSION: CT study with a dose of 24 g iodine showed equivalent quality on vascular enhancement in comparison with a 30 g iodine dose.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715674     DOI: 10.1007/bf02493279

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  15 in total

1.  Contrast-enhanced spiral CT of the head and neck: comparison of contrast material injection rates.

Authors:  R Groell; P Willfurth; G J Schaffler; R Mayer; F Schmidt; M M Uggowitzer; M Tillich; B Genser
Journal:  AJNR Am J Neuroradiol       Date:  1999-10       Impact factor: 3.825

2.  Cerebral tumor staging in patients with bronchial carcinoma by computed tomography.

Authors:  R Salbeck; H C Grau; H Artmann
Journal:  Cancer       Date:  1990-11-01       Impact factor: 6.860

3.  Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI.

Authors:  K Yokoi; N Kamiya; H Matsuguma; S Machida; T Hirose; K Mori; K Tominaga
Journal:  Chest       Date:  1999-03       Impact factor: 9.410

4.  The clinical evaluation for detecting metastatic lung cancer. A meta-analysis.

Authors:  G A Silvestri; B Littenberg; G L Colice
Journal:  Am J Respir Crit Care Med       Date:  1995-07       Impact factor: 21.405

5.  Cranial computed tomography as a part of the initial staging procedures for patients with non-small-cell lung cancer.

Authors:  D Ferrigno; G Buccheri
Journal:  Chest       Date:  1994-10       Impact factor: 9.410

6.  Brain metastasis in resected lung cancer: value of intensive follow-up with computed tomography.

Authors:  K Yokoi; N Miyazawa; T Arai
Journal:  Ann Thorac Surg       Date:  1996-02       Impact factor: 4.330

7.  Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases.

Authors:  G L Colice; J D Birkmeyer; W C Black; B Littenberg; G Silvestri
Journal:  Chest       Date:  1995-11       Impact factor: 9.410

8.  The noninvasive staging of non-small cell lung cancer: the guidelines.

Authors:  Gerard A Silvestri; Lynn T Tanoue; Mitchell L Margolis; John Barker; Frank Detterbeck
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

Review 9.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence.

Authors:  Eric M Toloza; Linda Harpole; Douglas C McCrory
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Intraparenchymal brain metastases: MR imaging versus contrast-enhanced CT.

Authors:  G Sze; J Shin; G Krol; C Johnson; D Liu; M D Deck
Journal:  Radiology       Date:  1988-07       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.